Disorganization of retinal inner layers as a biomarker in patients with center involving diabetic macular oedema treated with intravitreal bevacizumab - NI

K P Salve Institute of Medical Sciences and Research Centre , Nagpur0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1.Patients above 18 years of age, compliant for follow-up and willing to participate
•2.Patients of type I and type II Diabetes mellitus presenting with diabetic macular oedema resulting in visual loss
•3.Study eye having best corrected visual acuity of less than 6/12. Macular oedema defined clinically and by SD- OCT as retinal thickness of more than 250µm in the central sub-field and presence of intra or sub-retinal fluid .
•4.Treatment with intravitreal bevacizumab (atleast one injection) in past 6 months.

•1.Other retinal diseases which can cause macular oedema like retinal vascular disorders, choroidal neovascular membrane secondary to age related macular degeneration or any other cause, uveitis
•2.Recent history of any intraocular surgery leading to macular oedema
•3.Any other cause of loss of visual acuity except cataract

发起方

K P Salve Institute of Medical Sciences and Research Centre , Nagpur